$4.18
-0.11-2.56%
Dern. MÀJ: Oct 21, 4:00 PM
$4.18
-0.11-2.56%
ARS Pharmaceuticals (SPRY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.50 | $-0.53 | $-0.46 | $-0.47 |
| Actual | $-0.63 | $-0.61 | $-0.42 | $-0.52 |
| Surprise | -26.0% | -15.1% | +8.70% | -10.6% |
| Revenue | ||||
| Estimate | $31.4M | $22.1M | $25.6M | $28.6M |
| Actual | $33.7M | $22.7M | $28.1M | $32.5M |
| Surprise | +7.07% | +2.44% | +9.52% | +13.6% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.33 | $-0.27 | $-0.35 | $-0.21 |
| Revenue | ||||
| Consensus | $42.1M | $30.7M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-0.63 | $-0.50 | -26.0 % |
| Q1 | May 15, 2026 | $-0.61 | $-0.53 | -15.1 % |
| Q4 | Mar 9, 2026 | $-0.42 | $-0.46 | 8.70 % |
| Q3 | Nov 10, 2025 | $-0.52 | $-0.47 | -10.6 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $33.66M | $31.43M | 7.07 % |
| Q1 | May 15, 2026 | $22.68M | $22.14M | 2.44 % |
| Q4 | Mar 9, 2026 | $28.09M | $25.65M | 9.52 % |
| Q3 | Nov 10, 2025 | $32.50M | $28.60M | 13.6 % |